U.S., May 7 -- ClinicalTrials.gov registry received information related to the study (NCT06958536) titled 'A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease' on April 25.
Brief Summary: This is a phase 2, randomized, double-blind, 3-arm study for the treatment of Crohn's disease. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Crohn's disease. The total study duration is up to 168 weeks and the treatment duration is up to 158 weeks
Study Start Date: June 03
Study Type: INTERVENTIONAL
Condition:
Crohn's Disease
Intervention:
DRUG: SAR442970
Route of Administration: Subcutaneous
DRUG: Plac...